Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Follow the recommended dosage and duration provided by your healthcare professional
GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators
This triple receptor activity is the defining mechanistic feature that distinguishes Retatrutide from related compounds: Semaglutide acts on GLP-1R alone, while Tirzepatide targets GLP-1R and GIPR without glucagon receptor involvement
I mean, what are we doing here
US$ 26.95
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 26.72
US$ 27.59
,type=downsize)
